‘These Decisions Created A Lot Of Uncertainty’ – Why The Supreme Court’s Skinny-Label Ruling Matters

Hatch-Waxman & Biologics Chair Chad Landmon discusses the U.S. Supreme Court’s decision to review the induced infringement dispute between Hikma and Amarin, and the resulting uncertainty surrounding the effectiveness of skinny labels in avoiding induced infringement claims.